Leishmaniasis

Tonio V Piscopo, Charles Mallia Azzopardi

Epidemiology, disease patterns, immunology, diagnosis, treatment and control measures of leishmaniasis are described. Various issues relating to leishmaniasis are highlighted: the relative lack of importance given to this disease compared with other infections, climate change and its possible impact on extension of endemity of this infection, and new diagnostic tests which are improving diagnosis, especially in resource poor areas. Other important aspects discussed include the potential for newer oral therapy to change the way this disease is managed; Leishmania–HIV coinfection and groups at risk; and development of an effective vaccine.

Infectious diseases steal the headlines on a regular basis and are ranked high among other major news items like natural disasters, conflict situations and terrorism. Emerging infectious diseases with wide threatening potential such as severe acute respiratory syndrome and pandemic influenza, are usually the ones which get best coverage and consequently better funding. Diseases with high prevalence such as HIV/AIDS and malaria (table 1) should bring better financial returns from investing research into new treatments and developing vaccinations than similar investment into lower prevalence infections. Leishmaniasis is one such infection which rarely shares this limelight and thus remains largely a neglected disease.1,2

Despite this, several issues regarding leishmaniasis merit discussion: resistance to conventional drug treatment has developed in certain areas of the world, necessitating a change of first-line agents; rapid, less invasive diagnostic procedures have been developed which are most useful in poorly resourced parts of the world; despite advances in the understanding of the immunology of the disease and the unravelling of the Leishmania genome, a vaccine has not yet been developed; and the extent of disease in different individuals stresses the complex immunology of leishmaniasis, brought to the fore more recently with the advent of HIV–Leishmania coinfection, and its difficult eradication in this scenario.

This review is based on information from bibliographic research, Entrez-Pubmed searches on leishmaniasis, review articles and papers in their reference lists, and from the authors’ personal archives.

EPIDEMIOLOGY

Leishmaniasis is endemic in more than 60 countries worldwide,1 including Southern Europe, North Africa, the Middle East, Central and South America and the Indian subcontinent. It is not endemic in South East Asia and Australia.4 The burden of disease (90% of cases) is borne by Afghanistan, Pakistan, Syria, Saudi Arabia, Algeria, Iran, Brazil, and Peru in the case of cutaneous leishmaniasis, and by India, Bangladesh, Nepal, Sudan, and Brazil in the case of visceral leishmaniasis.5 Recently the number of reported cases and geographical areas have increased,6 and this has sparked concern regarding the contribution that global warming might have on this observation.7

One of the causative organisms of leishmaniasis, Leishmania donovani, was first described in 1901 by Leishman and Donovan almost simultaneously.8 Leishmania is a protozoon, able to infect animals, humans and sandflies. There are at least 20 species of Leishmania. Each may cause a disease specific to the species and the host response. Organism prevalence differs by geographical distribution. Thus disease patterns differ by geographical area (table 2).

The reservoirs of the disease are animals like canines and rodents (zoonotic cycle) and, in countries such as Sudan, humans (anthroponotic cycle).9 The sandfly is the vector of the disease and ingests the organism, as an amastigote, into its digestive tract when feeding on an infected animal. The amastigote develops into a promastigote in its digestive tract, and will then be injected into the susceptible host at the next feed. The promastigote then infects macrophages and develops into amastigotes (fig 1).

About 70 different species of sandfly can transmit leishmaniasis.10 The species are mainly Lutzomyia in the Americas and Phlebotomus elsewhere.11 The sandfly characteristically feeds at dusk, and being a weak flier, tends to remain close to its breeding area, not too high from the ground. Different species have different feeding and resting patterns. These different characteristics are important in formulating control strategies (see below).

The incidence and prevalence can be seen in table 1. Infection is more common in men than in women, but this may reflect increased exposure to sandflies. Although disease occurs irrespective of age, children aged 1–4 years are particularly at risk of infection in the Mediterranean regions, and childhood infection may account for more than half of all cases in some of these countries.12 Untreated visceral leishmaniasis carries a mortality of 75–95%, while cutaneous leishmaniasis can

Abbreviations: IFN, interferon; PCR, polymerase chain reaction; PKDL, post-kala azar dermal leishmaniasis; Th, T helper
disseminate to involve the mucosa, resulting in death from secondary infection.8

**DISEASE PATTERNS**

Three main types of disease patterns occur: visceral, cutaneous and mucocutaneous leishmaniasis (table 3). The type of disease expressed depends both on the type of *Leishmania* species and the zymodeme (electrophoretic isoenzyme pattern) expressed on that species. Thus one zymodeme may cause visceral leishmaniasis while another zymodeme of the same species may cause cutaneous leishmaniasis.14

**Visceral leishmaniasis**

The incubation period varies from 3 to 8 months15 16 (range 10 days17 to 34 months 18). Features include fever, weight loss, hepatosplenomegaly (usually spleen much larger than liver), lymphadenopathy, pancytopenia and hypergammaglobulinaemia.10 Skin pigmentation may be a feature (“kala azar”: black disease). It may be asymptomatic and self-resolving, but usually runs a chronic course and may be fatal without or despite treatment.19 Death usually occurs because of severe secondary bacterial infections in advanced disease.

Some cases of visceral leishmaniasis present atypically and cases have been reported which involve the lungs, pleura, oral mucosa, larynx, oesophagus, stomach, small intestine, skin and bone marrow.12

**Variations of visceral leishmaniasis**

Post-kala azar dermal leishmaniasis (PKDL) develops after resolution of visceral leishmaniasis. The time interval to development of PKDL is variable. PKDL occurs in a small percentage of patients in Africa and India.12 This is usually due to infection by the *L donovani* sensu stricto cluster.20 The skin lesions are macular, maculo-papular or nodular, and usually spread from the perioral area to other areas of the body.

**Cutaneous leishmaniasis**

This initially starts as a papule at the site of a sandfly bite which then increases in size, crusts (fig 2), and eventually ulcerates. It may take 3–18 months to heal in over 90% of cases.12 The incubation period lasts from 2 weeks to several months and cases up to 3 years have been reported in Old World cutaneous

---

**Table 1** Epidemiology of different infectious diseases

<table>
<thead>
<tr>
<th>Disease</th>
<th>Annual incidence (global)</th>
<th>Mortality: no of deaths per year (global)</th>
<th>Prevalence: total no of infected persons (global)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV/AIDS</td>
<td>5.6 million</td>
<td>2.6 million</td>
<td>34 million</td>
</tr>
<tr>
<td>Malaria</td>
<td>300 million</td>
<td>1–2.7 million</td>
<td>–</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>7.8 million</td>
<td>1.8 million</td>
<td>1.7 billion</td>
</tr>
<tr>
<td>Visceral leishmaniasis</td>
<td>500 000</td>
<td>80 000</td>
<td>12 million</td>
</tr>
<tr>
<td>Cutaneous leishmaniasis</td>
<td>1.5–2 million</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>


---

**Box 1: Current issues in *Leishmania* infection**

- *Leishmania* is given less importance than other more prevalent infectious diseases.
- Climate change may be responsible for the extension of endemicity of leishmaniasis to previously non-endemic countries.
- New diagnostic tests should improve diagnosis, especially in the field in resource-poor areas.
- *Leishmania* may relapse in HIV patients and is difficult to eradicate, if at all in this setting. There have been calls for Leishmania infection to be officially recognised as an AIDS-defining illness.
- Anthropogenic transmission may occur in intravenous drug users who share needles.
- The *Leishmania* genome has been unravelled, but an effective vaccine is not yet available.

---

**Table 2** Disease patterns and organisms prevalent in different geographical locations4 8 9 12

<table>
<thead>
<tr>
<th>Disease patterns</th>
<th>Old World organisms</th>
<th>New World organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral leishmaniasis</td>
<td><em>L. donovani</em> (India, Kenya)</td>
<td><em>L. chagasi</em></td>
</tr>
<tr>
<td></td>
<td><em>L. infantum</em> (Southern Europe and North Africa)</td>
<td><em>L. amazonensis</em></td>
</tr>
<tr>
<td></td>
<td><em>L. tropica</em></td>
<td></td>
</tr>
<tr>
<td>Post-kala azar dermal leishmanias</td>
<td><em>L. donovani</em> sensu stricto</td>
<td></td>
</tr>
<tr>
<td>Viscerotropic leishmaniasis</td>
<td><em>L. tropica</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. major</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. aethiopica</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. donovani</em></td>
<td></td>
</tr>
<tr>
<td>Cutaneous leishmaniasis</td>
<td><em>L. mexicana</em> species complex</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. mexicana</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. amazonensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. venezuelensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Viannia</em> subgenus</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. braziliensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. panamensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. guyanensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. peruviana</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. major-like organisms</em></td>
<td></td>
</tr>
<tr>
<td>Mucosal leishmaniasis</td>
<td><em>Viannia</em> subgenus</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. (V) braziliensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. (V) panamensis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. (V) guyanensis</em></td>
<td></td>
</tr>
<tr>
<td>Leishmaniasis recidivans</td>
<td><em>L. amazonensis</em> (see text)</td>
<td></td>
</tr>
<tr>
<td>Diffuse cutaneous leishmaniasis</td>
<td><em>L. aethiopica</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. major</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>L. mexicana</em> species complex</td>
<td></td>
</tr>
</tbody>
</table>

(V): refers to the *Viannia* subgenus. The leishmanias were classified into the subgenera Leishmania sensu stricto (Old and New World) and *Viannia* (New World) by Lainson and Shaw in 1987.9
Leishmaniasis. In New World cutaneous leishmaniasis, the incubation period is usually 2–8 weeks. Variations of cutaneous leishmaniasis

Leishmaniasis recidivans is characterised by tuberculoid lesions developing around scars of healed cutaneous ulcers, revealing a low parasite count on biopsy. Infections tend to be resistant to treatment.

In diffuse cutaneous leishmaniasis, dissemination of skin lesions rarely occurs over the face, hands and feet, revealing high parasite numbers due to poor cell-mediated immune response. This is more common in the New World *Leishmania* but also occurs with *L. aethiopica* in East Africa.

Mucocutaneous leishmaniasis

The incubation period is 1–3 months, but mucocutaneous leishmaniasis may occur many years after the initial cutaneous ulcer has healed. Mucosal involvement occurs in South American cases of cutaneous leishmaniasis (espundia) involving the nose, oral cavity and pharynx. This causes difficulty with eating and an increased risk of secondary infection which carries a significant mortality.

IMMUNOLOGY

The immune response (box 2) to *Leishmania* infection is cell mediated. The organism lies exclusively intracellularly, mainly inside macrophages as replicating amastigotes. The outcome of infection will depend on whether the host mounts primarily a T-helper (Th)-1 or Th2 response. Studies in animals suggest that the same parasite epitope can induce a Th1 response in animals with resolving infection or a Th2 response in others with disease progression. Other animal studies have shown that Th1 and natural-killer cells produce interferon γ (IFNγ), which mediates resistance, whilst interleukin (IL)4-producing Th2 cells confer susceptibility to infection. Human studies have also shown that IL4, a component of the Th2 response, may also be associated with disease progression.

In the Th1 response, promastigotes attach to reticuloendothelial cells and T helper CD4 cells produce IL2, IL3 and IFNγ which activate macrophages. IL2 and tumour necrosis factor (TNF) are also important in this type of response. The promastigotes are then phagocytosed by the activated macrophages into vacuoles which then fuse with lysosomes. Host genetics inevitably influence the type of immune response. Studies in mice and humans have shown that genes such as those coding for natural resistance associated macrophage protein 1 (NRAMP1), TNF or the major histocompatibility complex are thought to play a major role in the outcome of infection. The parasite itself can affect the macrophage and induces an immune response.

### Table 3: Leishmaniasis disease patterns

<table>
<thead>
<tr>
<th>Disease type</th>
<th>Incubation period</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral leishmaniasis</td>
<td>3–8 months (range 10 days to 34 months)</td>
<td>Fever, weight loss, hepatosplenomegaly, lymphadenopathy, pancytopenia and hypergammaglobulinaemia, skin pigmentation</td>
</tr>
<tr>
<td>Post-kala azar dermal leishmaniasis</td>
<td>Variable; develops after resolution of visceral leishmaniasis</td>
<td>Skin lesions around mouth and other parts of body</td>
</tr>
<tr>
<td>Cutaneous leishmaniasis</td>
<td>2 weeks to several months (rarely up to 3 years)</td>
<td>Papule at the site of a sandfly bite increases in size, crusts, and ulcerates</td>
</tr>
<tr>
<td>Leishmaniasis recidivans</td>
<td></td>
<td>Tuberculoid lesions develop around scars of healed cutaneous ulcers; low parasite count on biopsy</td>
</tr>
<tr>
<td>Diffuse cutaneous leishmaniasis</td>
<td></td>
<td>Rare. Dissemination of skin lesions occurs over face and extremities; high parasite numbers due to poor cell-mediated immune response</td>
</tr>
<tr>
<td>Mucocutaneous leishmaniasis</td>
<td>1–3 months (may occur many years after the initial cutaneous ulcer has healed)</td>
<td>Mainly in South America. Involves the nose, oral cavity and pharynx resulting in difficulty with eating</td>
</tr>
</tbody>
</table>
Box 2: The immune response

**Th1 immune response**
- T-helper CD4 cells producing IL2, IL3, IFN-γ
- Will promote immune responses that are primarily cell mediated/inflammatory by activating cytotoxic T cells, natural killer cells and macrophages
- In leishmaniasis, associated with disease resolution

**Th2 immune response**
- Th2 cells produce IL4, IL5, IL6, IL10 which favour induction of antibody responses by B cells
- In leishmaniasis, associated with disease progression

dendritic cell responses. Specific gene loci such as the A2 gene can code for products which promote *L. donovani* infectivity. Thus the interplay between the host-determined delayed-type hypersensitivity, antigen-specific T-cell reactivity, and cytokine secretion, and the type and virulence of the particular infecting *Leishmania* species determine what type of disease expression develops in the host.

Some cases are believed to harbour *Leishmania* organisms for indefinite periods before the disease is expressed, suggesting latent infection. Parasites have also been detected in lymph nodes after clinical cure. This is probably the basis of recrudescence of leishmaniasis which can occur decades after the initial infection, if cell-mediated immunity becomes disturbed. It is thought that “sterile” immunity—that is, complete eradication of the organism, probably rarely develops in visceral infection.

**DIAGNOSIS**

**Visceral leishmaniasis**

Diagnosis in visceral leishmaniasis is usually based on microscopic detection of amastigotes in smears of tissue aspirates or biopsy samples. Bone marrow aspirates or biopsy are frequently the tissues of choice with sensitivities in the 55–97% range (fig 1). Lymph node aspirate smears (sensitivity 60%) or biopsy, and splenic aspirates (sensitivity >97%) may also be taken for diagnosis, though the latter may give rise to life-threatening haemorrhage (table 4).

Sometimes the parasite can be cultured from microscopy negative tissue samples on special media like Novy, McNeal, Nicolle (NNN) medium or inoculated into animals such as hamsters.

*Leishmania* antibody (direct agglutination test) may be detected with a sensitivity of 72% and a specificity of 94%. Some cross-reactions in leprosy, Chagas disease, malaria, and schistosomiasis may occur. In HIV, antibodies to *Leishmania* may become undetectable.

Immunochromatographic strip testing of blood from a finger prick for leishmanial anti-K39 antibody has been used successfully in field serodiagnosis with a sensitivity of 90–100% in symptomatic patients. This test is useful in clinical management in resource-poor areas.

*Leishmania* DNA can also be detected in tissue aspirates and peripheral blood by polymerase chain reaction (PCR), with some series giving a sensitivity of 70–93% in peripheral blood. High sensitivities down to the level of one parasite have been recorded. Newer methods with high sensitivity and specificity include the detection of *Leishmania* antigen and antibody in the urine.

**Cutaneous leishmaniasis**

Diagnosis is usually based on microscopic examination of skin scrapings or biopsy specimens, usually taken from the edge of lesions. This is rapid and low-cost, but has limited sensitivity, especially in chronic lesions.

Cultures of the lesions, while more sensitive, may become contaminated by bacterial and fungal elements in the biopsy specimen itself. Also, different species have different growth requirements. *Leishmania* species may be identified using isoenzyme electrophoresis, but this is lengthy and expensive and necessitates cultivation of parasites on a large scale. Monoclonal antibodies can also be used for identification of

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Diagnostic methods</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Visceral leishmaniasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microscopic detection of amastigotes in smears of tissue aspirates or biopsy samples</td>
<td>Bone marrow aspirates or biopsy: sensitivity 55–97%</td>
<td></td>
</tr>
<tr>
<td>Tissue culture</td>
<td></td>
<td>Lymph node aspirate smears (sensitivity 60%) or biopsy</td>
</tr>
<tr>
<td>Leishmania antibody (DAT)</td>
<td></td>
<td>Spleen aspirates (sensitivity &gt;97%): risk of life-threatening haemorrhage</td>
</tr>
<tr>
<td>Anti-K39 antibody in blood droplet</td>
<td></td>
<td>Some cross-reactions in leprosy, Chagas disease, malaria, and schistosomiasis</td>
</tr>
<tr>
<td>Leishmania DNA detection in tissue aspirates and peripheral blood by PCR</td>
<td></td>
<td>In HIV, may be falsely negative</td>
</tr>
<tr>
<td>Detection of Leishmania antigen and antibody in the urine</td>
<td></td>
<td>Sensitivity 70–93% in peripheral blood</td>
</tr>
<tr>
<td><strong>Cutaneous leishmaniasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microscopic examination of skin scrapings or biopsy specimens taken from the edge of lesions</td>
<td>Rapid and low-cost Limited sensitivity, especially in chronic lesions</td>
<td></td>
</tr>
<tr>
<td>Cultures of the lesions</td>
<td></td>
<td>A practical guide to diagnostic techniques in cutaneous leishmaniasis can be found at: <a href="http://www.thelancet.com/journals/lancet/article/PIIS0140673698101782/fulltext/abstract">http://www.thelancet.com/journals/lancet/article/PIIS0140673698101782/fulltext/abstract</a> More sensitive than microscopy</td>
</tr>
<tr>
<td>Antibody detection</td>
<td></td>
<td>May become contaminated Different species have different growth requirements</td>
</tr>
<tr>
<td>Montenegro (leishmanin) skin test</td>
<td></td>
<td>Poorly sensitive In American cutaneous leishmaniasis there have been reports of cross-reactivity</td>
</tr>
</tbody>
</table>

DAT, direct agglutination test; PCR, polymerase chain reaction.
species in cultured strains, but direct analysis of clinical specimens is better achieved by using PCR, which is rapid, with high specificity and sensitivity. Detection and genetic characterisation of *Leishmania* can also be accomplished simultaneously. One study on American cutaneous leishmaniasis yielded a PCR sensitivity rate of 100%. Antibody detection is poorly sensitive due to a lack of significant antibody production in cutaneous leishmaniasis. Moreover, in American cutaneous leishmaniasis there have been reports of cross-reactivity of leishmanial antigens with antibodies induced by other kinetoplastids such as *Trypanosoma cruzi*. Other available means of diagnosing cutaneous leishmaniasis include the Montenegro (leishmanian skin test which detects specific cutaneous delayed-type hypersensitivity. It involves intradermal injection of *Leishmania* antigen, for example *L. Mexicana*, and monitoring for a local reaction. Limitations of this test include its inability to distinguish between current and past infection, as well as reports of false positivity in other skin infections.

**TREATMENT**

Recommended treatment regimens are summarised in table 5.

**Visceral leishmaniasis**

Treatment is largely based on pentavalent antimonials. Increasing resistance to antimonials is a major problem, and this is most evident in North Bihar, India, where the failure rate for this treatment is more than 50%. Pentavalent antimony (Sb(V)) can take the form of sodium stibogluconate (Sb(V) 100 mg/ml) or meglumine antimonate (Sb(V) 85 mg/ml). These can be given intravenously or intramuscularly with equal efficacy. It is usually administered at a dose of Sb(V) 20 mg/kg for 28 days, depending on the species and the clinical syndrome. A recent randomised trial in US military personnel showed a shorter, 10-day course to be equally effective. A maximum dose of 850 mg daily has been recommended in order to minimise side effects such as arrhythmias. Some experts, however, feel that this might predispose to resistance, and advocate higher doses. In some resistant cases of both visceral leishmaniasis and cutaneous leishmaniasis, IFN-gamma has been added successfully to Sb(V) to induce remission.

Amphotericin B is an effective treatment used in Sb(V)-resistant cases. It is toxic and needs to be given for a prolonged period on an inpatient basis. The alternative is to use the liposomal form, which is highly effective and less toxic, although up to now prohibitively expensive. The trend in Southern Europe is shifting towards using liposomal amphotericin B as first-line treatment, even though the response rate is still around 90% for antimonials. However, a recent trend in increasing resistance to pentavalent antimonials in this area has been recorded, possibly attributed to using meglumine antimonate to treat infected dogs. The effectiveness of short courses of this liposomal amphotericin B is resulting in improved cost-benefits. Studies using lower doses of this agent are also showing promise to improve cost-effective treatment in resource poor areas with high antimonial resistance.

Mifelefosine is the first effective orally active drug against leishmaniasis. Studies of treatment with this drug for 3 or 4 weeks have shown a cure rate of 95–100%. It has also compared very well (cure rate of 94%) with amphotericin B (cure rate 97%) at 6 months' follow-up. It has the added benefit of a very good safety profile. The potential for this drug for treatment of large numbers of patients as outpatients in resource-poor areas is high, though concerns about compliance and eventual resistance have been expressed.

Other effective drugs have been used in treating leishmaniasis. Pentamidine can be used in treatment-resistant cases of visceral leishmaniasis. Its use is limited by its substantial toxicity, necessitating close inpatient monitoring. Paromomycin (aminosidine) has been used effectively in resistant cases in North Bihar. Pending commercial availability, this treatment should offer cost savings, though issues of potential toxicity such as nephrotoxicity or ototoxicity may need further evaluation. Sitamaquine, another oral agent, is currently being evaluated in phase II studies in India. This drug has been associated with a 50–67% cure rate. The imidazole and triazole drugs are not recommended for use in visceral leishmaniasis.

**Cutaneous leishmaniasis**

In deciding the best mode of treatment of cutaneous leishmaniasis, some facts need to be considered. Old World cutaneous leishmaniasis is not a life threatening disease and >90% of patients heal spontaneously within 3–18 months. The outcome of cutaneous leishmaniasis in the New World depends on the infecting species and may vary from benign to more severe manifestations. It is thus important to try to identify the infecting species, either by knowing the endemic species of the specific geographical area, or by means of diagnostic procedures. This can throw light on the prognosis and management options.

Treatment of cutaneous leishmaniasis will accelerate cure and reduce scarring. This is especially important at cosmetically important sites. Options in the treatment of cutaneous leishmaniasis include local or systemic treatment. Criteria in favour of local treatment include: Old World cutaneous leishmaniasis; small, single lesions; lack of risk of development of mucocutaneous leishmaniasis, lack of lymph node metastases; and *L. mexicana* lesions. New World lesions except *L. mexicana*, mucosal or lymph node involvement and lesions refractory to local treatment would be indications for systemic treatment.

**Local treatment of cutaneous leishmaniasis**

Physical modes of treatment including cryotherapy have been employed with success ranging from 77% to 100% at 4 weeks. Local infrared heat lamps have also produced good results, although invariably accompanied by skin bulla formation.

Paromomycin (aminosidine) ointment is produced in two different formulations. When combined with methylbenzethonium chloride, it gives cure rates of 74–85%, which is more effective than when combined with urea. However, paromomycin-methylbenzethonium causes more severe local inflammatory reactions than paromomycin-urea.

Intralesional infiltration of the dermis and base of the lesion with pentavalent antimony may be performed. This is a relatively painful procedure which needs to be performed regularly every 1–2 weeks for about 3–8 times. The cure rate with this procedure is about 75%. If this is not effective, systemic therapy should be considered.

Imiquimod, a topical immunomodulator has been successfully used in combination with meglumine antimonate in cases resistant to meglumine alone.

**Systemic treatment of cutaneous leishmaniasis**

Systemic treatment with antimonials in general requires a 20-day course. *L. major*, *L. tropica* and *L. mexicana* usually respond to a 10-day course. Pentamidine has been used as first line
therapy in *L. guyanensis* infection, but studies with *L. panamensis*, *L. braziliensis* and *L. mexicana* have also given a cure rate of 96%, comparable to 91% with meglumine antimonate.\textsuperscript{65, 66} Of the imidazole/triazole drugs, oral flucconaol and ketoconazole has been found useful in *L. major* infections, with a cure rate of 79%.\textsuperscript{66} Ketoconazole has been studied in *L. braziliensis panamensis* with efficacy (74%) similar to that of stibogluconate (68%).\textsuperscript{67}

Oral miltefosine has been studied in Colombia and Guatemala, with short-term cure rates of 91% in areas where *L. (Y) panamensis* is common. In areas where *L. (Y) braziliensis* and *L mexicana mexicana* are common, the cure rate fell to 53%.\textsuperscript{67}

Liposomal amphotericin B has not been extensively studied in cutaneous leishmaniasis, but isolated reports of its use in resistant cases show its effectiveness.\textsuperscript{68, 69} Similarly, systemic aminosidine has not been commonly used, and a study comparing it to antimonials for *L braziliensis* cutaneous leishmaniasis was not in favour of its use in this form.\textsuperscript{69}

Allopurinol has shown some enhancing of antimonial activity, but its use alone has not shown any significant benefit.\textsuperscript{71}

**Mucocutaneous leishmaniasis**

Treatment of mucocutaneous leishmaniasis with antimonials is unsatisfactory, especially in severe disease.\textsuperscript{72} Amphotericin B\textsuperscript{73} and more recently liposomal amphotericin B have been used in difficult cases with success.\textsuperscript{74} Steroids may have to be used in cases where respiratory compromise is possible.

**Leishmania**–**HIV** coinfected

There needs to be a high index of suspicion in patients with HIV with the typical presentations of visceral leishmaniasis such as pyrexia, pancytopenia and hepatosplenomegaly. However, splenomegaly may be absent in HIV.\textsuperscript{75} Uncommon sites of infection, such as the gastrointestinal tract or the upper respiratory tract, are more frequent. Diagnosis is reached as for non-HIV patients except that the *Leishmania* antibody test (direct agglutination test) is frequently (42.6%) negative.\textsuperscript{76, 77} The highest prevalence of coinfected occurs in southwestern Europe, mostly in Spain.\textsuperscript{78} The main risk group is intravenous drug users and an anthropoontic cycle has been suggested where *Leishmania* organisms present in used syringes\textsuperscript{79} are inoculated intravenously.

The importance of cell-mediated immunity in controlling leishmaniasis in the long term is best illustrated in *Leishmania**–**HIV** coinfected. When visceral leishmaniasis occurs in a known HIV-positive patients or when someone with a history of visceral leishmaniasis acquires HIV, there is a high risk that the *Leishmania* infection will become intractable. Even after appropriate treatment of visceral leishmaniasis, *Leishmania**–**HIV** is associated with a high relapse rate of 52% after 1 month to 3 years.\textsuperscript{76} Visceral leishmaniasis in HIV infection is being proposed for inclusion in the Centers for Disease Control and Prevention CDC clinical category C for the definition of AIDS as an indicator disease.\textsuperscript{76}

Although treatment of coinfected has not been adequately studied, pentavalent antimonials are still used widely. The relapse rate does not appear to be affected by the type of treatment given according to a head-to-head study between meglumine antimonate and amphotericin B.\textsuperscript{80} Meglumine antimonate and liposomal amphotericin have only been compared in smaller studies; no differences were found.\textsuperscript{81} One study suggested a role for oral miltefosine when the above treatments have failed in coinfected individuals.\textsuperscript{82}

Secondary prophylaxis prevents relapse and improves survival.\textsuperscript{83} \textsuperscript{84} Both pentavalent antimonials administered once every 28 days\textsuperscript{84} and liposomal amphotericin B every 21 days may be used;\textsuperscript{85} no differences in efficacy have been found. Secondary prophylaxis should be continued at CD4 counts below 200/\textmu l. It may be safe to stop secondary prophylaxis at CD4 counts above 350/\textmu l and possibly even above 200/\textmu l while on effective antiretroviral treatment.\textsuperscript{86} Antiretroviral treatment has been effective in decreasing relapses of visceral leishmaniasis.\textsuperscript{86}

**CONTROL**

Control of leishmaniasis depends on the prevalent local epidemiological characteristics. Thus in areas where sandflies

\begin{table}
\centering
\begin{tabular}{|c|c|c|}
\hline
Disease pattern & Drug & Dose \\
\hline
Visceral leishmaniasis & Pentavalent antimony (as stibogluconate or meglumine antimonate) & 20 mg/kg/day IM or IV × 28 days \\
L (V) braziliensis & Liposomal amphotericin B & 2 mg/kg/day IV × 5 days \\
Mildefosine & 2.5 mg/kg/day PO (ad or bd) ×28 days \\
\hline
Mucocutaneous leishmaniasis & As with visceral leishmaniasis & 1 mg/kg IV qod ×20–30 doses \\
L brasiliensis & Amphotericin B & This may be better than antimonials in mucosal disease \\
\hline
Cutaneous leishmaniasis & Observation alone & L major (A) and L mexicana (B) \\
Pentavalent antimony (as stibogluconate or meglumine antimonate) & 20 mg/kg/day IM or IV ×20 days (≥10 days in L major, L tropica and L mexicana) & Some experts advise not to exceed 850 mg daily \\
Ketoconazole & 200 mg PO od & vs L major (A) \\
Paromomycin & 600 mg PO od ×28 days & vs L panamensis (A) \\
\hline
Mildefosine & 2.5 mg/kg PO od ×28 days & vs L mexicana (A) \\
Paromomycin & Intralesional: 1 ml per lesion qod ×8–15 times & vs L pananensis and L braziliensis \\
\hline
Pentamidine & 2–4 mg/kg od or every 2 days IV ×15 doses & vs L pananensis and L braziliensis \\
Paromomycin & Topical bd & vs L guyanensis (C) \\
\hline
\end{tabular}
\caption{Summary of recommended treatment regimens*}
\end{table}
Most vaccine research is targeted against cutaneous leishmaniasis; any effectiveness against visceral leishmaniasis is uncertain. Work on a vaccine against human visceral leishmaniasis has been less successful, but should be boosted following success with a cutaneous leishmaniasis vaccine. Work on a canine visceral leishmaniasis vaccine seems to be more advanced.

CONCLUSION

Leishmaniasis remains a problematic infection requiring either potentially toxic treatments or less toxic, but expensive drugs. However, the availability of newer oral agents may change the way this disease is managed. Relapse may occur, especially in situations where immunosuppression is present; secondary prophylaxis needs to be given in this setting. The combination of Leishmania, HIV and anthropotic transmission between injecting drug users heralds a potential for higher incidence rates in endemic countries with severe drug abuse problems. In the absence of an effective vaccine, and with extension of endemicity, possibly due to climate change, these problems may become worse.

MULTIPLE CHOICE QUESTIONS (TRUE/FALSE (T/F); ANSWERS AT END OF REFERENCES)

1. Epidemiology
(A) Leishmania is endemic in Australasia
(B) Leishmania can be transmitted through infected syringes
(C) The epidemiology of Leishmania is tightly knit with the epidemiology of the sandfly
(D) The sandfly usually bites during the day
(E) The number of countries where Leishmania is endemic is set to increase with global warming

2. Visceral leishmaniasis
(A) Is characterised by splenomegaly and pancytopenia
(B) Carries a low mortality if not treated
(C) The organism is characteristically extracellular
(D) Fatalities are usually the result of secondary bacterial infections
(E) Almost always responds to antimony products

3. Immunology
(A) An effective vaccine is available
(B) The body’s response to infection is T-cell mediated
(C) The disease manifestation depends on Leishmania species and host response
(D) Immunosuppression predisposes to Leishmania infection
(E) Leishmania organisms can remain dormant for years in the reticulo-endothelial system

4. Treatment
(A) Liposomal amphotericin is effective but very expensive
(B) There are no oral medications to effectively treat Leishmania
(C) Oral miltofisine is very effective in the treatment of kala azar
(D) Cutaneous Leishmania can be treated both by physical and pharmacological means
(E) Leishmania in the immunosuppressed usually necessitates secondary prophylaxis
5. Diagnosis

(A) Identification of amastigotes in tissue smears or histology are commonly used methods of diagnosis

(B) Antibody towards K39 antigen is proving useful, especially in field diagnosis of visceral leishmaniasis

(C) Tissue cultures are used routinely

(D) Splenic aspirates are very necessary and safely used

(E) Leishmania PCR is useless on blood samples

ACKNOWLEDGEMENT

We are grateful to Dr Paul Cusicki, Consultant Microbiologist St Luke’s Hospital, Malta, for his helpful comments during production of this review.

References


Leishmaniasis


ANSWERS

1. (A) F, (B) T, (C) T, (D) F, (E) T; 2. (A) T, (B) F, (C) F, (D) T, (E) F; 3. (A) F, (B) T, (C) T, (D) T, (E) T; 4. (A) T, (B) F, (C) T, (D) T, (E) T; 5. (A) T, (B) T, (C) F, (D) F, (E) F.

www.postgradmedj.com